RxDoctor Payments Data

Jonathan Clemons, PA

Physician Assistant · Olympia, WANPI 1073006235

Payments from drug & device makers

$1,150in general payments, 2019–2025

Across 30 payments — averaging $38.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$191
  • Procept Biorobotics Corporation$140
  • Progenics Pharmaceuticals, Inc.$135
  • AbbVie$132
  • Merck$106
  • Johnson & Johnson$80
  • plus $366 from 11 others

What the payments were for

  • Food & beverage$1,07093%
  • Education$807%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,150 in reported general payments places this provider in the 85th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$45,947
Medicare patients
277
Services billed
1,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron46$37,148
GemtesaVibegron21$14,234
Tamsulosin Hcl320$7,180
Methenamine Hippurate43$4,414
Estradiol39$3,124
Solifenacin Succinate88$2,447
Finasteride99$1,689
Alfuzosin Hcl ErAlfuzosin Hcl34$1,012
Potassium Citrate ErPotassium Citrate11$879
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst36$870
Testosterone Cypionate19$866
Dutasteride16$768
Oxybutynin Chloride66$648
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim82$644
Cefdinir13$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$27$14,23421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Olympia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →